Bayer’s Pipeline Refresh Focuses On Early Stage Despite Near-Term Growth Needs
Interview With Pharma R&D Head Christian Rommel
The company is struggling to grow revenue, and the biggest of its four key late-stage assets had a setback, but novel technologies are fueling an R&D strategy shift towards high potential programs.
